Measured Wealth Private Client Group, LLC Neurocrine Biosciences Inc Transaction History
Measured Wealth Private Client Group, LLC
- $364 Million
- Q3 2025
A detailed history of Measured Wealth Private Client Group, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Measured Wealth Private Client Group, LLC holds 140 shares of NBIX stock, worth $20,280. This represents 0.01% of its overall portfolio holdings.
Number of Shares
140Holding current value
$20,280% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
731Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...